<DOC>
	<DOC>NCT02206659</DOC>
	<brief_summary>To assess the trough/peak ratio of 40 mg Telmisartan tablet by ambulatory blood pressure monitoring in Chinese patients with mild to moderate essential hypertension</brief_summary>
	<brief_title>Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Chinese male or female aged 18 to 75 years Mild to moderate hypertension defined as a morning DBP _95 and &lt;110 mm Hg at visit1 and visit 2. Mean sitting systolic pressure (SBP) must be &lt;180 mm Hg Ability to provide written informed consent Women who are pregnant or breastfeeding, or of childbearing potential without an effective method of birth control (effective birth control methods are: uterine device, surgical sterilisation, progestogens alone) Known or suspected secondary hypertension Known history of any chronic hepatic disease Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; postrenal transplant New York Heart Association (NYHA) functional class congestive heart failure (CHF) IIIIV Unstable angina pectoris Myocardial infarction or percutaneous transluminal coronary angiography (PTCA) or cardiac surgery within the preceding three months Clinical relevant cardiac arrhythmias as determined by the clinical investigator Hypertrophic obstructive cardiomyopathy or clinically significant valvular disease Evidence of retinal hemorrhages/exudates Clinical significant hyperkalemia as defined by serum potassium level &gt;6.0 milliequivalents (mEq)/L Insulindependent diabetes mellitus Noninsulindependent diabetes mellitus with poor glucose control as defined by persistent fasting blood sugar &gt;200 mg/dl, peripheral neuropathy or autonomic neuropathy Known drug or alcohol dependency Administration of any diuretic, ACE inhibitor or angiotensin II receptor antagonist within two weeks before runin period Administration of medication known to affect blood pressure during trial period Patients receiving any investigational therapy within one month of signing the informed consent form Known hypersensitivity to any component of the formulation Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>